All News

What's on the agenda for FTP in the month to come?

Omicron EG.5 COVID-19 variant takes hold in the US, new inclusive blood donation guidance goes into effect, and the national uninsured rate reaches a new all-time low.

Drug Topics spoke with Peter Koo, PharmD, RPh at McKesson ideaShare 2023 about the launch of Foster & Thrive.

Hear the pharmacists from Eden Drug, Hazel Green, and Professional Pharmacy on their reactions to being a finalist for this award and more.

A Q&A with Marc Ost, co-owner of Eric’s RX Shoppe, which was one of the first community pharmacies to receive the new vaccine.

Afoxolaner, moxidectin, and pyrantel chewable tablets protect dogs from fleas, ticks, heartworm disease, roundworms, and hookworms.

Be sure to vote in this month's poll!

The risk of drug shortages is increasing as the long-term sustainability of generic manufacturing faces challenges, including low return on investment because of lowered prices, drug purchasers becoming more concentrated, and new generics facing slow adoption.

Quizartinib (Vanflyta) is an oral inhibitor of FLT3, and it specifically targets FLT3-ITD mutations, which drive cancer growth and contribute to increased risk of relapse and shorter overall survival.

Your weekly roundup of the latest news from Drug Topics®.

Chuck Waters, vice president of marketing, communications, and data strategy at American Pharmacies, shared why collaboration is so important for the company’s annual APEX event.

Methamphetamine deaths among American Indian and Native Alaskan men and women significantly increased between 1992 and 2019.

Your weekly roundup of the latest news from Drug Topics®.

A Kaiser Family Foundation analysis found the 10 drugs accounted for more than half of the increase in gross Part D spending from 2018 to 2021.

The news comes almost 2 weeks after Cyltezo’s entrance into the US biosimilars market as the first commercially available and FDA-approved interchangeable adalimumab biosimilar.

The approval of norgestrel (Opill) is expected to help reduce barriers to access by allowing people to obtain the medication without needing to see a health care provider.

Join industry experts on Saturday, June 15, to completely transform and revolutionize how you approach front- and back-end solutions within your pharmacy.

The company will also add Sandoz’s unbranded version of adalimumab to its National Preferred Formulary.

A recent study shows decreased use of multiple types of contraception among patients struggling with OUD.

The approval was based on a confirmatory trial that found the therapy slowed disease progression compared with placebo.

Researchers concluded that older patients with stable MS can stop taking disease-modifying therapy because risk of relapse is so small.

The increase is expected to be somewhat offset by the impact of biosimilars coming to market and more care being provided in outpatient settings.

What's on the agenda for FTP in the upcoming month?